Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to the Tax Cuts and Jobs Act H.R. 1 (115); issues relating to incentives for life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of US firms.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2017 · fourth_quarter · Q4
Issues relating to the expansion of jobs in New York state.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; issues relating to the labeling of generic drugs; issues relating to products containing high doses of acetaminophen; issues relating to drug compounding; issues relating to removal of FDA unapproved products from the market; opioid abuse legislation; issues relating to prescription drug pricing; issues relating to illegal marketing of Phenobarbital; issues relating to FDA approval of Adrenalin.
Source: Senate LDA
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Comprehensive Opioid Abuse Reduction Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Comprehensive Opioid Abuse Reduction Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Comprehensive Opioid Abuse Reduction Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Comprehensive Addiction and Recovery Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Comprehensive Addiction and Recovery Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Comprehensive Addiction and Recovery Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Medicaid Generic Drug Price Fairness Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Medicaid Generic Drug Price Fairness Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Medicaid Generic Drug Price Fairness Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Medicaid Generic Drug Price Fairness Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Medicaid Generic Drug Price Fairness Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
H.R. 160, Protect Medical Innovation Act of 2015; issues relating to life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
H.R. 160, Protect Medical Innovation Act of 2015; issues relating to international tax code; issues relating to foreign earnings.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R. 471, Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; issues related to REMS and physician certification for controlled substance prescribing; issues related to registration of controlled substances overseas.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R. 471, Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; issues related to bioequivalence and related administrative procedures; issues relating to products containing high doses of acetaminophen.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9, the Innovation Act; issues relating to the misuse of the inter partes review process.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; issues relating to data exclusivity; H.R. 9, the Innovation Act.
Supporting quality of life for prostate cancer patients.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R. 471, Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; issues related to REMS and physician certification for controlled substance prescribing; issues related to registration of controlled substances overseas.
Supporting quality of life for prostate cancer patients.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Supporting quality of life for prostate cancer patients.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R. 471, Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; issues related to bioequivalence and related administrative procedures; issues relating to products containing high doses of acetaminophen.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Medicaid Generic Drug Price Fairness Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Medicaid Generic Drug Price Fairness Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Safeguarding America's Pharmaceuticals Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for vacuum erection systems; FDA Proposed Generic Drug Labeling Rule.
Safeguarding America's Pharmaceuticals Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs.
Safeguarding America's Pharmaceuticals Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Safeguarding America's Pharmaceuticals Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for vacuum erection systems; FDA Proposed Generic Drug Labeling Rule.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs.
American Research and Competitiveness Act of 2014
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to incentives for life sciences research; Life Sciences Jobs and Investment Act; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); H.R. 4679/S. 2360 (Stop Corporate Inversions Act of 2014); H.R. 4438 (American Research and Competitiveness Act of 2014); H.R. 4 (Jobs for America Act); S. 2786 (Corporate Inverters Earnings Stripping Reform Act of 2014); H.R. 4870 (Department of Defense Appropriations Act, 2015, Amendment 910).
Issues relating to incentives for life sciences research; Life Sciences Jobs and Investment Act; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); H.R. 4679/S. 2360 (Stop Corporate Inversions Act of 2014); H.R. 4438 (American Research and Competitiveness Act of 2014); H.R. 4 (Jobs for America Act); S. 2786 (Corporate Inverters Earnings Stripping Reform Act of 2014); H.R. 4870 (Department of Defense Appropriations Act, 2015, Amendment 910).
Issues relating to incentives for life sciences research; Life Sciences Jobs and Investment Act; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); H.R. 4679 (Stop Corporate Inversions Act of 2014).
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs.
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for vacuum erection systems; FDA Proposed Generic Drug Labeling Rule.
Issues relating to incentives for life sciences research; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act).
Issues relating to incentives for life sciences research; Life Sciences Jobs and Investment Act; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); H.R. 4679/S. 2360 (Stop Corporate Inversions Act of 2014); H.R. 4438 (American Research and Competitiveness Act of 2014); H.R. 4 (Jobs for America Act); S. 2786 (Corporate Inverters Earnings Stripping Reform Act of 2014); H.R. 4870 (Department of Defense Appropriations Act, 2015, Amendment 910).
Issues relating to incentives for life sciences research; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); international tax issues; issues relating to House Ways and Means Committee tax reform discussion draft.
Issues relating to incentives for life sciences research; Life Sciences Jobs and Investment Act; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); H.R. 4679 (Stop Corporate Inversions Act of 2014).
Patent Transparency and Improvements Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013); legislation relating to abusive patent litigation.
Patent Transparency and Improvements Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013); legislation relating to abusive patent litigation.
Patent Transparency and Improvements Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013).
Patent Transparency and Improvements Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013).
Preserve Access to Affordable Generics Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013); legislation relating to abusive patent litigation.
Preserve Access to Affordable Generics Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013).
Preserve Access to Affordable Generics Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013); legislation relating to abusive patent litigation.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; patent reform; issues relating to misuse of the inter pares review process.
Issues relating to mass torts and class action reform.
Issues relating to the Tax Cuts and Jobs Act H.R. 1 (115); issues relating to incentives for life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of US firms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2017 · third_quarter · Q3
Issues relating to mass torts and class action reform.
Issues relating to incentives for life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of US firms.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids Issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; opioid abuse legislation; issues relating to prescription drug pricing; issues relating to the removal of Opana ER from the market; issues relating to illegal marketing of Phenobarbital; issues relating to FDA approval of Adrenalin; issues relating to the compounding of Vasostrict; issues relating to FDA compounding regulations.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; patent reform; issues relating to misuse of the inter pares review process.
Issues relating to the expansion of jobs in New York state.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2017 · second_quarter · Q2
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; issues relating to products containing high doses of acetaminophen; Issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; opioid abuse legislation; issues relating to prescription drug pricing; issues relating to removal of Opana ER from the market; issues relating to illegal marketing of phenobarbital; issues relating to FDA approval of adrenaline.
Issues relating to incentives for life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of US firms.
Issues relating to mass torts and class action reform.
Issues relating to the expansion of jobs in New York state.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; patent reform; issues relating to misuse of the inter pares review process.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2017 · first_quarter · Q1
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; issues relating to products containing high doses of acetaminophen; issues relating to removal of FDA unapproved products from the market; opioid abuse legislation; issues relating to prescription drug pricing.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; patent reform; issues relating to misuse of the inter pares review process; issues relating to Mass Tort/Class Action Reform
Issues relating to incentives for life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of US firms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2016 · fourth_quarter · Q4
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2016 · third_quarter · Q3
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2016 · first_quarter · 1A
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2016 · second_quarter · Q2
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2016 · first_quarter · Q1
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2015 · fourth_quarter · Q4
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2015 · third_quarter · Q3
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2015 · second_quarter · Q2
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9, the Innovation Act; issues relating to the misuse of the inter partes review process.
H.R. 160, Protect Medical Innovation Act of 2015; issues relating to life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R. 471, Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; issues related to bioequivalence and related administrative procedures; issues relating to products containing high doses of acetaminophen.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2015 · first_quarter · Q1
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R. 471, Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; issues related to REMS and physician certification for controlled substance prescribing; issues related to registration of controlled substances overseas.
H.R. 160, Protect Medical Innovation Act of 2015; issues relating to international tax code; issues relating to foreign earnings.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2014 · fourth_quarter · Q4
Issues related to tamper resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act.
Issues relating to incentives for life sciences research; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act).
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013).
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2014 · third_quarter · Q3
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013); legislation relating to abusive patent litigation.
Issues relating to incentives for life sciences research; Life Sciences Jobs and Investment Act; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); H.R. 4679/S. 2360 (Stop Corporate Inversions Act of 2014); H.R. 4438 (American Research and Competitiveness Act of 2014); H.R. 4 (Jobs for America Act); S. 2786 (Corporate Inverters Earnings Stripping Reform Act of 2014); H.R. 4870 (Department of Defense Appropriations Act, 2015, Amendment 910).
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2014 · second_quarter · Q2
Issues related to tamper resistant forumulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act.
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013); legislation relating to abusive patent litigation.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2014 · first_quarter · Q1
Issues relating to incentives for life sciences research; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); international tax issues; issues relating to House Ways and Means Committee tax reform discussion draft.
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2013 · fourth_quarter · Q4
Issues relating to patent settlements, including S. 214, the Preserve Access to Affordable Generics Act H.R. 3309 The Innovation Act Oversight of implementation of the America Invents Act
Issues relating to international tax policy Issues relating to the medical device tax H.R. 523/S. 232--Protect Medical Innovation Act of 2013
H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013 Compounding and drug supply chain legislation H.R. 3204 -- Drug Quality and Security Act Issues relating to products containing high doses of acetaminophenIssues relating to the rescheduling of products containing hydrocodone Issues relating to Veterans' access to certain topical pain therapies Issues relating to Medicare Part D rebates Issues relating to awareness of low testosterone and other urological conditions Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013 Issues relating to bioequivalence and related administrative procedures
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2013 · third_quarter · Q3
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
Oversight of implementation of the America Invents Act Issues relating to patent settlements Legislation relating to abusive patent litigation
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3204 -- Compounding and drug supply chain legislation H.R. 984 -- Urotrauma legislation U.S. Preventive Services Task Force recommendations on PSA testing for prostate cancer
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2013 · second_quarter · Q2
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013 Life Sciences Jobs and Investment Act
Oversight of implementation of the America Invents Act Issues relating to patent settlements Legislation relating to abusive patent litigation
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2013 · first_quarter · Q1
Issues relating to incentives for life science research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
Oversight of implementation of the America Invents Act. Issues realting to patent settlements
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · fourth_quarter · Q4
Oversight of implementation of the America Invents Act.
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
H.R. 3010, Regulatory Accountability Act of 2011.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · third_quarter · Q3
H.R. 3010, Regulatory Accountability Act of 2011.
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · second_quarter · Q2
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012; S. 3187, FDA Safety and Innovation Act; issues relating to bioequivalence and related administrative procedures; issues relating to DEA quotas for controlled substances; oversight of DEA; issues relating to prescription drug abuse.
Oversight of implementation of the America Invents Act.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · first_quarter · Q1
Patent reform issues (H.R. 1249, S. 23); Pattent settlements (S. 27).
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410).
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2011 · fourth_quarter · Q4
Patent reform issues (H.R. 1249, S. 23); Pattent settlements (S. 27).
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410)
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674)
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2011 · third_quarter · Q3
Patent reform issues (H.R. 1249, S. 23); Pattent settlements (S. 27).
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation; Healthcare reform bill repeal (H.R. 2); Orphan drugs issues; Drug Shortage issues (S. 296); medical liabilty reform.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2011 · second_quarter · Q2
Patent reform issues (H.R. 1249, S. 23); Pattent settlements (S. 27).
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation; Healthcare reform bill repeal (H.R. 2); Orphan drugs issues; Drug Shortage issues (S. 296); medical liabilty reform.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2011 · first_quarter · Q1
Patent reform issues (H.R. 1249, S. 23); Pattent settlements (S. 27).
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation; Healthcare reform bill repeal (H.R. 2); Orphan drugs issues.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2010 · fourth_quarter · Q4
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359, Safe Drug Disposal Act of 2009 H.R. 1191, H.R. 5809, S. 3397, S. 1292 & S. 1336); drug reimportation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); reauthorization of Prescription Drug User Fee Act; health care technical corrections (H.R. 5712); life sciences research tax credit legislation (H.R. 6165).
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2010 · third_quarter · Q3
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359, Safe Drug Disposal Act of 2009 H.R. 1191, H.R. 5809, S. 3397, S. 1292 & S. 1336); drug reimportation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); reauthorization of Prescription Drug User Fee Act; health care technical corrections (H.R. 5712); life sciences research tax credit legislation (H.R. 6165).
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2010 · second_quarter · Q2
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Lobbying on scope of Physician Payments Sunshine Act (S. 301); general Medicare and Medicade reform issues (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S. 1679); electronic prescribing issues (no specific legislation); anti-counterfeiting legislation concerning drugs/pedigree drug legislation; legislation on drug and device safety (Food and Drug Administration Globalization Act of 2009 H.R. 759); generic drug legislation (H.R. 573); follow-on biologics (Pre-existing Condition Patient Protection Act of 2009 S. 623); Medicare Prescription Drug Savings and Choice Act of 2009 (S. 330 & H.R. 684); drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359 and Safe Drug Disposal Act of 2009 H.R. 1191, S. 1292, S. 1336); federal preemption issues in Medical Device Safety Act of 2009 (S. 540 and H.R. 1346); National Pain Care Policy Act of 2009 (H.R. 756 & S. 660); drug reimportation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); disposal of drugs (H.R. 1191, H.R. 1359, S. 1292 & S. 1336); biosimilar drugs (H.R. 1427, H.R. 1548, S. 726); tax on pharmaceutical companies (H.R. 3590, S. 1796); health care reform (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S. 1679, America's Healthy Future Act S. 1796, H.R. 3590, H.R. 3962, H.R. 3200, H.R. 4872); modify approval of oxycodone (H.R. 4956); reauthorization of Prescription Drug User Fee Act; health care technical corrections (H.R. 5712); life sciences research tax credit legislation.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2010 · first_quarter · Q1
Miscellaneous Tax Issues
Lobbying on scope of Physician Payments Sunshine Act (S. 301); general Medicare and Medicade reform issues (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S 1679); electronic prescribing issues (no specific legislation); anti-counterfeiting legislation concerning drugs/pedigree drug legislation; legislation on drug and device safety (Food and Drug Administration Globalization Act of 2009 H.R. 759); generic drug legislation (H.R. 573); follow-on biologics (Pre-existing Condition Patient Protection Act of 2009 S. 623); Medicare Prescription Drug Savings and Choice Act of 2009 (S. 330 & H.R. 684); drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359 and Safe Drug Disposal Act of 2009 H.R. 1191, S. 1292, S. 1336); federal preemption issues in Medical Device Safety Act of 2009 (S. 540 and H.R. 1346); National Pain Care Policy Act of 2009 (H.R. 756 & S. 660); drug reimportation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); disposal of drugs (H.R. 1191, H.R. 1359, S. 1292, & S. 1336); biosimilar drugs (H.R. 1427, H.R. 1548, S. 726); tax on pharmaceutical companies (H.R. 3590, S. 1796); health care reform (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S. 1679, America's Healthy Future Act S. 1796, H.R. 3590, H.R. 3962, H.R. 3200, H.R. 4872); modify approval of oxycodone (H.R. 4956); reauthorization of Prescription Drug User Fee Act.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2009 · fourth_quarter · Q4
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Lobbying on scope of Physician Payments Sunshine Act (S. 301); general Medicare and Medicade reform issues (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S 1679); electronic prescribing issues (no specific legislation); pedigree drug legislation; legislation on drug and device safety (Food and Drug Administration Globalization Act of 2009 H.R. 759); generic drug legislation (H.R. 573); follow-on biologics (Pre-existing Condition Patient Protection Act of 2009 S. 623); Medicare Prescription Drug Savings and Choice Act of 2009 (S. 330 & H.R. 684); drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359 and Safe Drug Disposal Act of 2009 H.R. 1191); federal preemption issues in Medical Device Safety Act of 2009 (S. 540 and H.R. 1346); National Pain Care Policy Act of 2009 (H.R. 756 & S. 660); drug importation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); disposal of drugs (H.R. 1191, H.R. 1359, S. 1292, & S. 1336); biosimilar drugs (H.R. 1427, H.R. 1548, S. 726); tax on pharmaceutical companies (H.R. 3590, S. 1796); health care reform (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S. 1679, America's Healthy Future Act S. 1796, H.R. 3590, H.R. 3962).
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2009 · third_quarter · Q3
Lobbying on scope of Physician Payments Sunshine Act (S. 301); general Medicare and Medicade reform issues (no specific legislation); electronic prescribing issues (no specific legislation); pedigree drug legislation; legislation on drug and device safety (Food and Drug Administration Globalization Act of 2009 H.R. 759); generic drug legislation (H.R. 573); follow-on biologics (Pre-existing Condition Patient Protection Act of 2009 S. 623); Medicare Prescription Drug Savings and Choice Act of 2009 (S. 330 & H.R. 684); drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359 and Safe Drug Disposal Act of 2009 H.R. 1191); federal preemption issues in Medical Device Safety Act of 2009 (S. 540 and H.R. 1346); National Pain Care Policy Act of 2009 (H.R. 756 & S. 660); drug importation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); disposal of drugs (H.R. 1191, H.R. 1359, S. 1292, & S. 1336); health care reform (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S. 1679, & America's Healthy Future Act).
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2009 · second_quarter · Q2
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Lobbying on scope of Physician Payments Sunshine Act (S. 301); general Medicare and Medicade reform issues (no specific legislation); electronic prescribing issues (no specific legislation); pedigree drug legislation; legislation on drug and device safety (Food and Drug Administration Globalization Act of 2009 H.R. 759); generic drug legislation (H.R. 573); follow-on biologics (Pre-existing Condition Patient Protection Act of 2009 S. 623); Medicare Prescription Drug Savings and Choice Act of 2009 (S. 330 & H.R. 684); drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359 and Safe Drug Disposal Act of 2009 H.R. 1191); federal preemption issues in Medical Device Safety Act of 2009 (S. 540 and H.R. 1346); National Pain Care Policy Act of 2009 (H.R. 756 & S. 660); drug importation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); disposal of drugs (H.R. 1191, H.R. 1359, S. 1292, & S. 1336); health care reform.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2009 · first_quarter · Q1
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Lobbying on scope of Physician Payments Sunshine Act (S. 301); general Medicare and Medicade reform issues (no specific legislation); electronic prescribing issues (no specific legislation); pedigree drug legislation; legislation on drug and device safety (Food and Drug Administration Globalization Act of 2009 H.R. 759); generic drug legislation (H.R. 573); follow-on biologics (Pre-existing Condition Patient Protection Act of 2009 S. 623); Medicare Prescription Drug Savings and Choice Act of 2009 (S. 330 & H.R. 684); drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359 and Safe Drug Disposal Act of 2009 H.R. 1191); federal preemption issues in Medical Device Safety Act of 2009 (S. 540 and H.R. 1346); National Pain Care Policy Act of 2009 (H.R. 756 & S. 660); drug importation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298).
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2008 · fourth_quarter · Q4
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2008 ( H.R. 1908 & S.1145)
Support National Pain Care Policy Act of 2007 (HR 2994) and Military Pain Care Act of 2008 (HR 5465); lobbying on scope of Physician Payments Sunshine Act of 2007 (S.2029); general Medicare and Medicade reform issues (no specific legislation); Safeguarding America's Pharmaceuticals Act of 2008 (HR 5839); electronic prescribing issues (no specific legislation); pedigree drug legislation (Safeguarding Americas Pharmaceuticals Act, H.R. 5839)
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2008 · third_quarter · Q3
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2008 ( H.R. 1908 & S.1145)
Supported Veterans Pain Care Act of 2007 (S. 2160)
Support National Pain Care Policy Act of 2007 (HR 2994) and Military Pain Care Act of 2008 (HR 5465); lobbying on scope of Physician Payments Sunshine Act of 2007 (S.2029); general Medicare reform issues (no specific legislation); Safeguarding America's Pharmaceuticals Act of 2008 (HR 5839); electronic prescribing issues (no specific legislation)
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2008 · second_quarter · Q2
Support National Pain Care Policy Act of 2007 (HR 2994) and Military Pain Care Act of 2008 (HR 5465); lobbying on scope of Physician Payments Sunshine Act of 2007 (S.2029); general Medicare reform issues (no specific legislation); Safeguarding America's Pharmaceuticals Act of 2008 (HR 5839); electronic prescribing issues (no specific legislation)
Supported Veterans Pain Care Act of 2007 (S. 2160)
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2008 ( H.R. 1908 & S.1145)
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2008 · first_quarter · Q1
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2008 ( H.R. 1908 & S.1145)
Support National Pain Care Policy Act of 2007 (HR 2994) and Military Pain Care Act of 2008 (HR 5465); lobbying on scope of Physician Payments Sunshine Act of 2007 (S.2029); general Medicare reform issues (no specific legislation)
Supported Veterans Pain Care Act of 2007 (S. 2160)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2008 · first_quarter · RR
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tamper-resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act.
Oversight of implementation of the America Invents Act; issues relating to patent settlements; issues relating to data exclusivity; H.R. 9, the Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for vacuum erection systems; FDA Proposed Generic Drug Labeling Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs.
Issues related to tamper resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to incentives for life sciences research; Life Sciences Jobs and Investment Act; H.R. 523/S. 232 (Protect Medical Innovation Act of 2013/Medical Device Access and Innovation Protection Act); H.R. 4679 (Stop Corporate Inversions Act of 2014).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Oversight of implementation of the America Invents Act; issues relating to patent settlements, including S. 214 (Preserve Access to Affordable Generics Act); H.R. 3309 (The Innovation Act); S. 1720 (Patent Transparency and Improvements Act of 2013).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tamper resistant formulation of pharmaceutical drugs Life Sciences Jobs and Investment Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Oversight of implementation of the America Invents Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 3010, Regulatory Accountability Act of 2011.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Miscellaneous Tax Issues
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Supported Veterans Pain Care Act of 2007 (S. 2160)
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).
Issues related to electronic/online perscriptions; Medicare reform; corporate tax issues; and regulation of controlled substances; National Pain Care Policy Act of 2007 (H. R. 2994); Veterans Pain Care Act of 2007 (S. 2160); and Physician Payments Sunshine Act of 2007 (S. 2029).